Almost every medicine you've ever taken works on the same general principle: it adds something to the body — a chemical that blocks a process, replaces a missing substance, or kills an invader — and you keep taking it because the effect wears off. Gene therapy proposes something far more ambitious. Instead of managing the downstream effects of a faulty gene for the rest of your life, it aims to fix the gene itself, ideally with a single treatment. When it works, it can change a lifelong disease into a one-time event.
The basic idea
Many diseases come from a single broken instruction in your DNA. A gene that should produce a working protein instead produces a broken one, or none at all. In hemophilia, the missing protein is a clotting factor. In some inherited forms of blindness, it's a protein the retina needs to sense light. In spinal muscular atrophy, it's a protein motor neurons need to survive.
Gene therapy's answer is direct: deliver a correct copy of that gene into the cells that need it, so they can finally make the protein themselves. You're not topping up the missing protein from outside; you're giving the body the instructions to produce it on its own.
The delivery problem
The hard part isn't designing the corrected gene — it's getting it inside cells. DNA injected on its own gets destroyed and can't cross into a cell's nucleus on its own. So gene therapy needs a delivery vehicle, called a vector. And it turns out evolution already built the perfect delivery machine: the virus. Viruses exist to insert their genetic material into our cells. Scientists hollow them out, strip away the genes that cause disease, and load them with the therapeutic gene instead.
The most common vehicle today is the adeno-associated virus, or AAV — a small, naturally harmless virus that's good at delivering genes to specific tissues like the liver, eye, or muscle. Other approaches use a modified lentivirus, often outside the body: a patient's own cells are removed, corrected in the lab, and returned. The CAR-T cancer therapies are a specialized version of exactly this technique.
In the body versus in the lab
That distinction is worth drawing out, because it splits gene therapy into two broad styles.
- In vivo ("in the living body") — the vector is infused or injected directly into the patient, and it travels to the target cells on its own. This is how treatments for inherited blindness and certain clotting disorders work.
- Ex vivo ("outside the body") — cells are collected from the patient, corrected in a lab, grown, and then returned. This suits diseases of the blood and immune system, where the relevant cells can be removed and replaced.
Why it can be a one-time treatment — usually
If the corrected gene lands in long-lived cells, the effect can last for years or even a lifetime, because those cells keep following the new instructions. That's the dream: one infusion, lasting benefit. But there are caveats. In tissues whose cells keep dividing, the added gene can get diluted out over time as new cells are made without it. And because most people's immune systems will recognize the viral vector after the first exposure, giving a second dose of the same vector is difficult — the body neutralizes it. So gene therapy often has, in effect, one shot to get it right.
The risks
Gene therapy carries risks that are different in kind from ordinary drugs, which is why it's studied so cautiously. The immune system can react to the viral vector, sometimes strongly, particularly at the high doses needed to reach enough cells. There's the historical concern of where exactly the new gene inserts itself into the genome — if it lands in the wrong spot it could, in rare cases, disturb other genes. Modern vectors are designed to minimize this, but long-term follow-up is part of why these therapies are tracked for years after treatment. These are not small considerations, and they're a major reason the field moves deliberately.
Why a single dose costs millions
The price tags attached to approved gene therapies — often well over a million dollars — shock people, and the reasons are worth understanding. These are individualized biological products, manufactured in tiny batches under extreme quality control, frequently for very rare diseases where development costs are spread across only a few hundred patients. The pricing argument made by manufacturers is that a one-time cure replaces a lifetime of expensive ongoing care. Whether that math holds, and how health systems should pay for it, is one of the genuinely unsettled debates in modern medicine.
The short version
Gene therapy delivers a working copy of a faulty gene into your cells — usually carried by a hollowed-out, harmless virus — so the body can make a protein it was missing. Done in the body or in the lab, it aims to treat the root cause of a disease in a single shot rather than manage symptoms forever. The trade-offs are real: immune reactions, the difficulty of redosing, and staggering cost. To see which inherited and acquired conditions are being targeted in active studies, our gene therapy clinical trials overview follows the field.